Valneva’s Critical Juncture: Lyme Disease Vaccine Holds Key to Survival

Financial Forecasts Dim Following FDA Decision

The French vaccine developer Valneva finds itself at a pivotal moment, with its future prospects increasingly tied to the success of its Lyme disease vaccine candidate. A recent regulatory setback in the United States has forced the company to confront significant financial challenges, even as it secures substantial new funding to continue operations.

Valneva has substantially lowered its revenue projections for 2025 in the wake of an unfavorable decision from the U.S. Food and Drug Administration regarding its chikungunya vaccine, IXCHIQ®. The company now anticipates product revenues will fall between €155 million and €170 million, a notable reduction from previous guidance of €170-180 million. Similarly, total revenue expectations have been adjusted downward from €180-190 million to a range of €165-180 million.